<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="769">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117403</url>
  </required_header>
  <id_info>
    <org_study_id>IA0067</org_study_id>
    <nct_id>NCT00117403</nct_id>
  </id_info>
  <brief_title>Anti-Oxidant Treatment of Alzheimer's Disease</brief_title>
  <official_title>Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Disease Cooperative Study (ADCS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Aging (NIA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and effectiveness of two anti-oxidant&#xD;
      treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant&#xD;
      treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxidative damage has been shown to be a factor in Alzheimer's disease (AD), and some studies&#xD;
      have suggested that supplemental anti-oxidants can decrease the risk of AD or slow its&#xD;
      progression. There are many candidate antioxidants, including combinations, which could be&#xD;
      neuroprotective in established AD or could have efficacy in the prevention of AD. However,&#xD;
      testing each of the possibilities in standard clinical trials is prohibitively expensive.&#xD;
      This study will examine antioxidant supplements or vitamins which target specific cellular&#xD;
      compartments, and look for evidence of biologically relevant effects in AD by measurement of&#xD;
      biomarkers in CSF.&#xD;
&#xD;
      Two general cellular compartments where antioxidant supplements may act are the cytosol and&#xD;
      mitochondria. The study will examine a combination of antioxidants that act primarily at&#xD;
      cytosolic sites (vitamin E + C + Î±-lipoic acid) and a single mitochondrial antioxidant,&#xD;
      coenzyme Q10.&#xD;
&#xD;
      This multicenter trial will recruit 75 participants who will be randomized into three groups:&#xD;
&#xD;
        1. 25 participants will be given a combination of vitamin E 800 IU, vitamin C 200 mg, and&#xD;
           alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times&#xD;
           per day with meals, plus two placebo wafers three times per day with meals;&#xD;
&#xD;
        2. 25 participants will be given CoQ 400 mg, compounded as a wafer, two wafers three times&#xD;
           per day with meals, plus one placebo capsule three times per day with meals;&#xD;
&#xD;
        3. 25 participants will be given both the placebo wafers, two wafers three times per day&#xD;
           with meals, plus one placebo capsule three times per day with meals.&#xD;
&#xD;
      The treatment period will last four months. The effects of the two anti-oxidant treatments&#xD;
      will be evaluated by measuring biomarkers in blood and cerebrospinal fluid (CSF) at the&#xD;
      beginning and end of the 4-month period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effect on cerebrospinal fluid (CSF) biomarkers related to oxidative damage</measure>
    <time_frame>baseline and 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in plasma and CSF concentrations of a-beta42 and a-beta40</measure>
    <time_frame>baseline and 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals, plus two placebo wafers three times per day with meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CoQ 400 mg, compounded as a wafer, two wafers three times per day with meals, plus one placebo capsule three times per day with meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two placebo wafers three times per day with meals, plus one placebo capsule three times per day with meals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E, Vitamin C, and Alpha-lipoic Acid</intervention_name>
    <description>vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme Q</intervention_name>
    <description>400 mg, compounded as a wafer, two wafers three times per day with meals</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>one placebo capsule three times per day with meals</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo wafers</intervention_name>
    <description>two placebo wafers three times per day with meals</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women aged 60-85, inclusive&#xD;
&#xD;
          -  Diagnosis of probable Alzheimer's disease&#xD;
&#xD;
          -  English-speaking; Spanish-speaking if individual site allows&#xD;
&#xD;
          -  Study partner or caregiver to assure compliance&#xD;
&#xD;
          -  Mini-Mental State Examination score at screening visit greater than 14&#xD;
&#xD;
          -  Female participants either surgically sterile or postmenopausal for over 1 year&#xD;
&#xD;
          -  Stable medical condition for 3 months prior to screening, with no significant abnormal&#xD;
             liver, kidney, or blood studies&#xD;
&#xD;
          -  Stable medications for 4 weeks prior to screening&#xD;
&#xD;
          -  Able to take oral medications&#xD;
&#xD;
          -  Modified Hachinski Ischemic Index less than or equal to 4&#xD;
&#xD;
          -  CT or MRI since onset of memory impairment demonstrating the absence of a clinically&#xD;
             significant focal lesion&#xD;
&#xD;
          -  Physically acceptable for this study as confirmed by medical history, physical exam,&#xD;
             neurological exam, and clinical tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant neurologic disease such as Parkinson's disease, stroke, brain tumor,&#xD;
             multiple sclerosis, or seizure disorder&#xD;
&#xD;
          -  Major depression in the past 12 months, major mental illness such as schizophrenia, or&#xD;
             recent (in past 12 months) alcohol or substance abuse&#xD;
&#xD;
          -  History of invasive cancer within the past two years (excluding non-melanoma skin&#xD;
             cancer)&#xD;
&#xD;
          -  Contra-indications to lumbar puncture&#xD;
&#xD;
          -  Use of any investigational agents within 30 days prior to screening&#xD;
&#xD;
          -  Major surgery within 8 weeks prior to the Baseline Visit&#xD;
&#xD;
          -  Uncontrolled cardiac conditions or severe unstable medical illnesses&#xD;
&#xD;
          -  Antiretroviral therapy for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Conditions that will contribute to oxidative stress: current cigarette or cigar&#xD;
             smokers (within past month), diabetics on insulin or poorly controlled on oral&#xD;
             hypoglycemics&#xD;
&#xD;
          -  Residence in skilled nursing facility&#xD;
&#xD;
          -  Blindness, deafness, language difficulties or any other disability which may prevent&#xD;
             the participant from participating or cooperating in the protocol&#xD;
&#xD;
        Note: Exceptions to these criteria may be considered on a case-by-case basis, at the&#xD;
        discretion of the Project Director.&#xD;
&#xD;
        Excluded Medications:&#xD;
&#xD;
          -  Experimental drugs&#xD;
&#xD;
          -  Coumadin&#xD;
&#xD;
          -  Insulin&#xD;
&#xD;
          -  Immunosuppressive agents: prednisone and other corticosteroids (taken orally or by&#xD;
             injection), methotrexate, cyclophosphamide, cyclosporin, tacrolimus, etc.&#xD;
&#xD;
          -  HIV protease inhibitors&#xD;
&#xD;
          -  Neuroleptics and lithium&#xD;
&#xD;
          -  Anti-cancer agents (exception: stable doses of hormonal therapy, e.g. Lupron,&#xD;
             estrogen, are permitted)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Galasko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California- Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wien Center, Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Care of CNY</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997 Apr 24;336(17):1216-22.</citation>
    <PMID>9110909</PMID>
  </reference>
  <reference>
    <citation>Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol. 1999 Feb;57(3):301-23. Review.</citation>
    <PMID>10096843</PMID>
  </reference>
  <reference>
    <citation>Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC; Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004 Jan;61(1):82-8.</citation>
    <PMID>14732624</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2005</study_first_posted>
  <last_update_submitted>April 1, 2009</last_update_submitted>
  <last_update_submitted_qc>April 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Paul Aisen, MD</name_title>
    <organization>Alzheimer's Disease Cooperative Study</organization>
  </responsible_party>
  <keyword>dementia</keyword>
  <keyword>anti-oxidant</keyword>
  <keyword>biomarkers</keyword>
  <keyword>alpha-tocopherol</keyword>
  <keyword>CoQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

